Aberdeen Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Aberdeen Group’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.37M	Sell	297,512 -90,398	-23%	-$2.15M	0.01%	638
2025 Q4	$9.05M	Sell	387,910 -244,531	-39%	-$5.45M	0.01%	625
2025 Q3	$12.5M	Sell	632,441 -56,319	-8%	-$1.16M	0.02%	564
2025 Q2	$14.9M	Sell	688,760 -76,534	-10%	-$1.81M	0.03%	494
2025 Q1	$18.6M	Buy	765,294 +280,628	+58%	+$6.32M	0.04%	414
2024 Q4	$10.1M	Buy	+484,666	New	+$10.4M	0.02%	508

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Aberdeen Group's CPRX Position: Q1 2026 in Review

Aberdeen Group reduced its Catalyst Pharmaceutical (CPRX) stake by 23% in Q1 2026, selling an estimated $2.15M and leaving 297,512 shares worth $7.37M. The position accounts for 0.01% of the portfolio, ranked #638.

Aberdeen Group first reported a position in CPRX in Q4 2024 and has held it in 6 quarters since. The position peaked at $18.6M in Q1 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Aberdeen Group held 297,512 shares of Catalyst Pharmaceutical worth $7.37M as of Q1 2026.
Aberdeen Group sold 90,398 Catalyst Pharmaceutical shares in Q1 2026, an estimated $2.15M.
Catalyst Pharmaceutical made up 0.01% of Aberdeen Group's portfolio in Q1 2026, its #638 holding.
Aberdeen Group first reported a position in Catalyst Pharmaceutical in Q4 2024 and has held it in 6 quarters since.
Aberdeen Group's Catalyst Pharmaceutical position peaked at $18.6M in Q1 2025.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Aberdeen Group's 13F filing for Q1 2026, filed 29 Apr 2026.